Peijia Medical Ltd. (HK:9996) has released an update.
Peijia Medical Ltd. has reported strong interim results for the first half of 2024, with a notable 33.9% increase in revenue and a substantial decrease in losses compared to the prior year. The company has expanded its presence in the Chinese transfemoral TAVR market, achieving nearly 25% market share, and has significantly optimized expense ratios across various departments. Additionally, Peijia Medical has made progress in its research and development pipeline, with several core clinical trials completed and new products entering the market.
For further insights into HK:9996 stock, check out TipRanks’ Stock Analysis page.
